Globus Medical, Inc. (NYSE:GMED) to Post FY2026 Earnings of $3.77 Per Share, Zacks Research Forecasts

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for shares of Globus Medical in a note issued to investors on Monday, May 6th. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings of $3.77 per share for the year, up from their prior forecast of $3.76. The consensus estimate for Globus Medical’s current full-year earnings is $2.69 per share.

GMED has been the topic of several other research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $70.00 target price on shares of Globus Medical in a report on Thursday, January 11th. Stifel Nicolaus increased their price objective on shares of Globus Medical from $64.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday. Truist Financial lifted their target price on Globus Medical from $58.00 to $60.00 and gave the stock a “hold” rating in a report on Wednesday, February 21st. Piper Sandler lifted their price objective on Globus Medical from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $66.60.

Globus Medical Stock Up 20.0 %

NYSE GMED opened at $61.61 on Thursday. Globus Medical has a 12 month low of $43.38 and a 12 month high of $65.74. The company has a current ratio of 4.88, a quick ratio of 2.72 and a debt-to-equity ratio of 0.10. The stock has a market cap of $8.34 billion, a PE ratio of 52.66, a P/E/G ratio of 1.53 and a beta of 1.11. The stock’s 50 day moving average is $52.50 and its 200 day moving average is $51.26.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Tuesday, May 7th. The medical device company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.17. The business had revenue of $606.67 million for the quarter, compared to analysts’ expectations of $586.82 million. Globus Medical had a return on equity of 8.82% and a net margin of 7.83%. The business’s quarterly revenue was up 119.3% on a year-over-year basis. During the same period last year, the firm earned $0.53 earnings per share.

Institutional Investors Weigh In On Globus Medical

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Globus Medical by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 11,277,722 shares of the medical device company’s stock worth $600,990,000 after buying an additional 32,220 shares during the period. Nuance Investments LLC boosted its position in Globus Medical by 36.8% during the third quarter. Nuance Investments LLC now owns 3,620,518 shares of the medical device company’s stock valued at $179,759,000 after purchasing an additional 974,693 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Globus Medical by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 3,016,702 shares of the medical device company’s stock valued at $161,816,000 after purchasing an additional 110,912 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Globus Medical by 9.5% in the 4th quarter. Wellington Management Group LLP now owns 2,912,454 shares of the medical device company’s stock valued at $155,205,000 after buying an additional 252,510 shares in the last quarter. Finally, William Blair Investment Management LLC boosted its holdings in shares of Globus Medical by 1.9% in the 3rd quarter. William Blair Investment Management LLC now owns 2,316,372 shares of the medical device company’s stock valued at $115,008,000 after buying an additional 43,187 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insider Transactions at Globus Medical

In related news, Director Leslie V. Norwalk sold 10,590 shares of Globus Medical stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $51.99, for a total transaction of $550,574.10. Following the completion of the sale, the director now owns 17,419 shares in the company, valued at approximately $905,613.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 24.30% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.